Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescentsArticle Published on 2022-12-202023-07-11 Journal: Cell Reports [Category] COVID19(2023년), [키워드] antibody broad-spectrum cocktail CP: Immunology CP: Microbiology omicron Prophylactics Sarbecovirus. SARS-CoV-2 [DOI] 10.1016/j.celrep.2022.111845 PMC 바로가기
A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and TreatmentArticle Published on 2022-09-092022-11-15 Journal: Viruses [Category] SARS, 변종, 진단, [키워드] Alpha VOC Analysis antibody approved AZD7442 baseline cilgavimab Clinical data Clinical efficacy cocktail Combination conducted control arm convalescent plasma COVID-19 creating Delta VOC dominant early treatment Efficacy Evidence Evusheld Fc fragment high risk Immune escape Immunocompromised Immunocompromised patient Immunoglobulin indicated ingredient LAAB mAb monoclonal antibody monotherapy omicron Patient Prophylaxis Randomized controlled trial Regulatory robust subject subjects suggested the SARS-CoV-2 therapeutic Therapies Tixagevimab tixagevimab. Treatment Trial trials variant viral loads VoC [DOI] 10.3390/v14091999 PMC 바로가기
Clinical efficacy of casirivimab-imdevimab antibody combination treatment in patients with COVID-19 Delta variant코로나19 델타 변이형 환자에서 카시리비맙-임데비맙 항체 병용요법의 임상적 효능Article Published on 2022-09-012022-09-11 Journal: Journal of infection and chemotherapy : official j [Category] COVID19(2023년), SARS, 변종, 임상, 진단, 치료법, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus 2 administration age antibody cocktail antibody combination antibody treatment Casirivimab Casirivimab-imdevimab treatment clinical Clinical efficacy cocktail Combination conducted control group coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient death Delta delta variant dose Efficacy evaluate FIVE High flow nasal cannula high-risk patient High-risk patients hospital Hospitalization Imdevimab inclusion criteria intravenously Japan mechanical ventilation monoclonal antibodies monoclonal antibody nasal nasal cannula Neutralizing antibodies outcome oxygen Oxygen therapy Patient patients with COVID-19 receive reduce reduced respiratory risk SARS-CoV-2 SARS-CoV-2. significantly lower therapy Treatment treatment group Viral Viral load with COVID-19 [DOI] 10.1016/j.jiac.2022.05.012 PMC 바로가기 [Article Type] Article
High titer of antibody against the SARS-CoV-2 spike protein among patients receiving neutralizing antibody cocktail therapy with REGN-COVREGN-COV로 중화 항체 칵테일 요법을 받는 환자 중 SARS-CoV-2 스파이크 단백질에 대한 높은 항체가Article Published on 2022-06-012022-09-11 Journal: Infection [Category] COVID19(2023년), SARS, 진단, 치료법, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration antibody Antibody titer Antibody titers Architect body weight Casirivimab casirivimab/imdevimab clinical benefit cocktail collected coronavirus coronavirus disease Coronavirus disease 2019 correlated COVID-19 effective elevated evaluated IgG Imdevimab Immunoglobulin Linear regression model median Neutralizing antibodies neutralizing antibody nine nucleocapsid protein Patient patients with COVID-19 Prophylactic Prophylaxis receiving Receptor-binding domain REGN-COV remained respiratory SARS-CoV-2 SARS-CoV-2 IgG SARS-CoV-2. serological serological data severe acute respiratory syndrome Coronavirus shown simple linear regression Spike protein Support the receptor-binding domain the SARS-CoV-2 therapeutic therapy treated Treatment were assessed [DOI] 10.1007/s15010-022-01779-x PMC 바로가기 [Article Type] Article
Ex vivo and in vivo suppression of SARS-CoV-2 with combinatorial AAV/RNAi expression vectors조합 AAV/RNAi 발현 벡터를 사용한 SARS-CoV-2의 생체외 및 생체내 억제Article Published on 2022-05-042022-09-11 Journal: Molecular therapy : the journal of the American So [Category] COVID19(2023년), SARS, 변종, 치료제, [키워드] AAV acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition adeno-associated virus Antiviral Antiviral agents antiviral RNAi Cell clinically cocktail complement coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 disease symptom effective escape mutant escape mutants experiment expression vector flexible Genetic global effort Gut hACE2 in vivo infected cell infected cells intestinal cells intranasal mice mutational escape. N gene N genes organoids pandemic prevented RdRP RNA RNAi SARS virus SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 RdRp SARS-CoV-2 strains severe acute respiratory syndrome Coronavirus suppressed the SARS-CoV-2 therapeutic translation triggers Vaccine vector vectors viral adaptation Viral load viral loads virus wild-type [DOI] 10.1016/j.ymthe.2022.01.024 PMC 바로가기 [Article Type] Article
Melatonin and REGN-CoV2 combination as a vaccine adjuvant for Omicron variant of SARS-CoV-2SARS-CoV-2의 오미크론 변이체에 대한 백신 보조제로서의 멜라토닌 및 REGN-CoV2 조합Review Published on 2022-05-012022-09-11 Journal: Molecular biology reports [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adjuvant adjuvant therapy affected antioxidant Antiviral caused cocktail Combination contagiousness coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 cytokine Cytokine storm delta variant develop elderly patients evaluate Immunocompromised immunomodulatory effects less mAb mAb cocktails mAbs melatonin multiple mutation multiple mutations Mutation neutralizing monoclonal antibodies neutralizing monoclonal antibody omicron Omicron variant Panic Prevent prevention of COVID-19 RBD Receptor binding domain Regeneron REGN-CoV2 REGN-COV2. respiratory SARS-CoV-2 severe acute respiratory syndrome Coronavirus severe symptom shown Spike protein the spike protein therapy traction treat Treatment Vaccine variant of SARS-CoV-2 Viral viral invasion [DOI] 10.1007/s11033-022-07419-9 PMC 바로가기 [Article Type] Review
Cocktail of REGN Antibodies Binds More Strongly to SARS-CoV-2 Than Its Components, but the Omicron Variant Reduces Its Neutralizing AbilityREGN 항체 칵테일은 성분보다 SARS-CoV-2에 더 강하게 결합하지만 오미크론 변이체는 중화 능력을 감소시킵니다Article Published on 2022-04-212022-09-11 Journal: The journal of physical chemistry. B [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] Ability antibody antiviral antibodies antiviral antibody appear approach association bind binding calculated change coarse-grained simulation coarse-grained simulations cocktail complexes components computational method contribute COVID-19 infections Delta delta variant dissociation constants driven by effective Effectiveness electrostatic interaction electrostatic interactions Infection Interaction interactions K417N molecular molecular dynamics molecular mechanism molecular mechanisms Mutation neutralize Neutralizing activity omicron Omicron variant RBD Receptor-binding domain reduce REGN10933 REGN10987 SARS-CoV-2 SARS-CoV-2 spike protein shown Spike protein Structure structures the receptor-binding domain the SARS-CoV-2 Treatment treatment of COVID-19 understanding van der Waal van der Waals interactions variant virus [DOI] 10.1021/acs.jpcb.2c00708 PMC 바로가기 [Article Type] Article
Bivalent H1 and H3 COBRA Recombinant Hemagglutinin Vaccines Elicit Seroprotective Antibodies against H1N1 and H3N2 Influenza Viruses from 2009 to 2019Article Published on 2022-04-132023-06-14 Journal: Journal of Virology [Category] Fulltext, 신종인플루엔자, [키워드] Bivalent bivalent vaccine broadly reactive antibody Cobra cocktail H1N1 H3N2 hemagglutinin hemagglutinin vaccine Imprinting Influenza preimmunity universal influenza. [DOI] 10.1128/jvi.01652-21 PMC 바로가기
Impact of Antibody Cocktail Therapy Combined with Casirivimab and Imdevimab on Clinical Outcome for patients with COVID-19 in A Real-Life Setting: A Single Institute Analysis카시리비맙 및 임데비맙과 결합된 항체 칵테일 요법이 실제 환경에서 COVID-19 환자의 임상 결과에 미치는 영향: 단일 기관 분석Article Published on 2022-04-012022-09-12 Journal: International Journal of Infectious Diseases [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] 95%CI Analysis analyzed antibody cocktail Casirivimab clinical Clinical practice clinical trial cocktail Combined COVID-19 COVID-19 pandemic death effective Factor high-risk patient hospital Hospitalization Hospitalized Imdevimab Impact initial Isolation medical intervention oxygen saturation Patient patients with COVID-19 recent reduced reducing reduction REGEN-COV risk Ronapreve SARS-CoV-2 SARS-CoV-2. significantly therapy with COVID-19 [DOI] 10.1016/j.ijid.2022.01.067 PMC 바로가기 [Article Type] Article
Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta VariantSARS-CoV-2 Delta 변이에 감염된 백신 접종 환자에서 Casirivimab/Imdevimab 단일클론항체 치료 효과Article Published on 2022-03-212022-09-11 Journal: Viruses [Category] SARS, 변종, 진단, 치료기술, [키워드] acute respiratory syndrome Analysis B.1.617.2 Casirivimab casirivimab/imdevimab Chest Chest computed tomography clinical clinical evolution clinical manifestations Clinical presentations cocktail Computed tomography coronavirus coronavirus 2 Delta delta variant Disease progression early stage early stages Effect effective Efficacy evaluated Evolution FIVE Hospitalized Imdevimab Infection mAb mAbs monoclonal antibodies monoclonal antibody monoclonal antibody treatment Nasopharyngeal swab nasopharyngeal swabs Next-generation sequencing NGS outcomes Patient patients performed prevent disease progression real-time RT-PCR Regression respiratory Respiratory failure Safe SARS-CoV-2 Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 submitted Symptom Symptoms thymoma Treatment Vaccine variant variants variants of concern variants of concern. Viral viral load reduction [DOI] 10.3390/v14030650 PMC 바로가기 [Article Type] Article